Primary Surgery or Interval Debulking for Advanced Epithelial Ovarian Cancer: Does It Matter?

被引:26
作者
Markauskas, Algirdas [1 ]
Mogensen, Ole [1 ]
Christensen, Rene dePont [2 ]
Jensen, Pernille Tine [1 ]
机构
[1] Odense Univ Hosp, Dept Obstet & Gynaecol, DK-5000 Odense C, Denmark
[2] Univ Southern Denmark, Res Unit Gen Practice, Odense, Denmark
关键词
Debulking surgery; Epithelial ovarian cancer; Surgical complexity; Postoperative morbidity; Survival; NEOADJUVANT CHEMOTHERAPY; CYTOREDUCTIVE SURGERY; QUALITY; RISK;
D O I
10.1097/IGC.0000000000000241
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Objective: The aim of the present study was to investigate the surgical complexity, the postoperative morbidity, and the survival of the women after primary debulking surgery (PDS) and neoadjuvant chemotherapy followed by interval debulking surgery (NACT-IDS) for advanced epithelial ovarian cancer. Materials and Methods: We consecutively included all patients who underwent debulking surgery at our institution between January 2007 and December 2012 for stages IIIc and IV of epithelial ovarian cancer. Results: Of the 332 patients included, 165 (49.7%) underwent PDS, and 167 (50.3%) had NACT-IDS. Complete intraperitoneal cytoreduction was achieved in 70.9% after PDS and in 59.9 % after NACT-IDS. Residual disease of greater than 1 cm was left in 18.5% and 27.5% after PDS and NACT-IDS, respectively. Compared with NACT-IDS, PDS was associated with higher surgical complexity (P < 0.001), longer operating time (P < 0.001), greater blood loss (P < 0.001), longer hospitalization (P = 0.001), and a higher rate of major postoperative complications (26.7% vs 16.8%). No statistical difference in the median overall survival (OS) was found between the patients having complete cytoreduction and residual disease of 1 cm or less after NACT-IDS. Furthermore, no statistical difference in the median OS was found between the patients with macroscopic residual disease (<= 1 vs >1 cm) after NACT-IDS. Patients with residual disease of greater than 1 cm after PDS had a median OS of 15 months. Conclusions: We suggest that NACT-IDS may be a better treatment alternative for the group of highly selected women not suitable for PDS, where expected suboptimal cytoreduction does not have any appreciable survival benefit and exposes them for unnecessary risks. A substantial number of women who receive either PDS or NACT-IDS have greater than 1 cm of tumor tissue left after the operation. These women probably have no survival benefit from the operation, and future studies should focus on how to select these women preoperatively.
引用
收藏
页码:1420 / 1428
页数:9
相关论文
共 23 条
  • [1] A new frontier for quality of care in gynecologic oncology surgery: Multi-institutional assessment of short-term outcomes for ovarian cancer using a risk-adjusted model
    Aletti, Giovanni D.
    Santillan, Antonio
    Eisenhauer, Eric L.
    Hu, Jae
    Aletti, Giacomo
    Podratz, Karl C.
    Bristow, Robert E.
    Chi, Dennis S.
    Cliby, William A.
    [J]. GYNECOLOGIC ONCOLOGY, 2007, 107 (01) : 99 - 106
  • [2] Identification of patient groups at highest risk from traditional approach to ovarian cancer treatment
    Aletti, Giovanni D.
    Eisenhauer, Eric L.
    Santillan, Antonio
    Axtell, Allison
    Aletti, Giacomo
    Holschneider, Christine
    Chi, Dennis S.
    Bristow, Robert E.
    Cliby, William A.
    [J]. GYNECOLOGIC ONCOLOGY, 2011, 120 (01) : 23 - 28
  • [3] [Anonymous], 1978, Natl Cancer Inst Monogr
  • [4] Intraperitoneal cisplatin and paclitaxel in ovarian cancer
    Armstrong, DK
    Bundy, B
    Wenzel, L
    Huang, HQ
    Baergen, R
    Lele, S
    Copeland, LJ
    Walker, JL
    Burger, RA
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2006, 354 (01) : 34 - 43
  • [5] Bookman MA, 2000, PRINCIPLES PRACTICE, P404
  • [6] Delaying the primary surgical effort for advanced ovarian cancer: A systematic review of neoadjuvant chemotherapy and interval cytoreduction
    Bristow, Robert E.
    Eisenhauer, Eric L.
    Santillan, Antonio
    Chi, Dennis S.
    [J]. GYNECOLOGIC ONCOLOGY, 2007, 104 (02) : 480 - 490
  • [7] Platinum-based neoadjuvant chemotherapy and interval surgical cytoreduction for advanced ovarian cancer: A meta-analysis
    Bristow, Robert E.
    Chi, Dennis S.
    [J]. GYNECOLOGIC ONCOLOGY, 2006, 103 (03) : 1070 - 1076
  • [8] What is the optimal goal of primary cytoreductive surgery for bulky stage IIIC epithelial ovarian carcinoma (EOC)?
    Chi, D. S.
    Eisenhauer, E. L.
    Lang, J.
    Huh, J.
    Haddad, L.
    Abu-Rustum, N. R.
    Sonoda, Y.
    Levine, D. A.
    Hensley, M.
    Barakat, R. R.
    [J]. GYNECOLOGIC ONCOLOGY, 2006, 103 (02) : 559 - 564
  • [9] An analysis of patients with bulky advanced stage ovarian, tubal, and peritoneal carcinoma treated with primary debulking surgery (PDS) during an identical time period as the randomized EORTC-NCIC trial of PDS vs neoadjuvant chemotherapy (NACT)
    Chi, Dennis S.
    Musa, Fernanda
    Dao, Fanny
    Zivanovic, Oliver
    Sonoda, Yukio
    Leitao, Mario M.
    Levine, Douglas A.
    Gardner, Ginger J.
    Abu-Rustum, Nadeem R.
    Barakat, Richard R.
    [J]. GYNECOLOGIC ONCOLOGY, 2012, 124 (01) : 10 - 14
  • [10] The incidence of major complications after the performance of extensive upper abdominal surgical procedures during primary cytoreduction of advanced ovarian, tubal, and peritoneal carcinomas
    Chi, Dennis S.
    Zivanovic, Oliver
    Levinson, Kimberly L.
    Kolev, Valentin
    Huh, Jae
    Dottino, Joseph
    Gardner, Ginger J.
    Leitao, Mario M., Jr.
    Levine, Douglas A.
    Sonoda, Yukio
    Abu-Rustum, Nadeem R.
    Brown, Carol L.
    Barakat, Richard R.
    [J]. GYNECOLOGIC ONCOLOGY, 2010, 119 (01) : 38 - 42